- Home
- SKE vs ADPT Comparison
SKE vs ADPT Comparison
Compare SKE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- ADPT
- Stock Information
- Founded
- SKE 1979
- ADPT 2009
- Country
- SKE Canada
- ADPT United States
- Employees
- SKE N/A
- ADPT N/A
- Industry
- SKE Precious Metals
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKE Basic Materials
- ADPT Health Care
- Exchange
- SKE Nasdaq
- ADPT Nasdaq
- Market Cap
- SKE 997.4M
- ADPT 1.1B
- IPO Year
- SKE N/A
- ADPT 2019
- Fundamental
- Price
- SKE $10.09
- ADPT $7.67
- Analyst Decision
- SKE
- ADPT Strong Buy
- Analyst Count
- SKE 0
- ADPT 5
- Target Price
- SKE N/A
- ADPT $9.40
- AVG Volume (30 Days)
- SKE 402.2K
- ADPT 2.2M
- Earning Date
- SKE 05-09-2025
- ADPT 05-06-2025
- Dividend Yield
- SKE N/A
- ADPT N/A
- EPS Growth
- SKE N/A
- ADPT N/A
- EPS
- SKE N/A
- ADPT N/A
- Revenue
- SKE N/A
- ADPT $178,957,000.00
- Revenue This Year
- SKE N/A
- ADPT $21.21
- Revenue Next Year
- SKE N/A
- ADPT $21.98
- P/E Ratio
- SKE N/A
- ADPT N/A
- Revenue Growth
- SKE N/A
- ADPT 5.10
- 52 Week Low
- SKE $4.10
- ADPT $2.28
- 52 Week High
- SKE $11.74
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- SKE 48.36
- ADPT 47.20
- Support Level
- SKE $9.94
- ADPT $6.92
- Resistance Level
- SKE $10.62
- ADPT $9.01
- Average True Range (ATR)
- SKE 0.42
- ADPT 0.62
- MACD
- SKE -0.02
- ADPT 0.04
- Stochastic Oscillator
- SKE 38.89
- ADPT 51.36
About SKE Skeena Resources Limited
Skeena Resources Ltd is a Canadian mining exploration company focused on developing prospective precious and base metal properties in the Golden Triangle of northwest British Columbia, Canada. The company's primary activity is the exploration and development of the past-producing Eskay Creek mine acquired from Barrick.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).